查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403392

到 2030 年中和抗体市场预测：按抗体类型、配销通路、应用、最终用户和地区进行的全球分析

Neutralizing Antibody Market Forecasts to 2030 - Global Analysis By Antibody Type, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球中和抗体市场规模为 1,904 亿美元，预计在预测期内复合年增长率为 10.6%，到 ​​2030 年将达到 3,854 亿美元。

免疫系统产生一种称为中和抗体的抗体。这些抗体旨在选择性地靶向并抑制细菌和病毒等病原体的作用。这些抗体透过与病原体表面的特定区域结合来阻止病原体感染或伤害宿主细胞。这些抗体透过阻止病原体进入细胞和繁殖来帮助免疫系统管理和治癒感染。

根据 GLOBOCAN 2020 报告，全球将有 1,930 万人新诊断出癌症，约 1,000 万人将死于癌症。

感染疾病增加

肝炎、爱滋病毒/爱滋病和呼吸道感染疾病感染疾病在世界各地仍然相当普遍。控制这些疾病的一个有前途的治疗策略是使用中和抗体。随着这些感染疾病发生率的上升，对中和抗体的需求应该会越来越大。此外，由于自体免疫疾病盛行率的上升，预计市场将会扩大。

监管挑战

新型抗体疗法要获得监管部门的批准，需要对其安全性和有效性进行彻底评估。监管机构通常需要全面的临床资料，这可能会延长开发时间并增加成本。公司可能难以适应法规环境，尤其是涉及独特且复杂的中和抗体时。市场可能会受到监管问题的严重限制。

改进抗体工程和设计

抗体工程和设计方法的不断进步使我们能够生产优化的中和抗体。亲和性成熟和抗体人源化是用于提高抗体安全性、半衰期和功效的两种技术。抗体片段和抗体药物复合体等新平台的添加增加了治疗药物开发的潜力。这是市场拓展的主要因素。

开发和治疗成本高

创建和製造中和抗体的过程既昂贵又耗时。高开发成本是由于大量的研发活动、临床试验和製造成本。此外，中和抗体疗法非常昂贵，这可能会限制获得治疗的机会，特别是在预算和资源匮乏的医疗保健系统中。

COVID-19 的影响：

中和抗体市场受到了 COVID-19 大流行的严重影响。中和抗体对于治疗和预防 COVID-19 至关重要。几种单株抗体疗法已被核准或清除用于紧急情况。由于对 SARS-CoV-2 中和抗体的需求迅速增加，该市场显着增长。

单株抗体领域预计将成为预测期内最大的市场

单株抗体细分市场预计将成为预测期内最大的细分市场。对单株抗体产品的需求、不断扩大的製药和生物技术领域以及医疗保健行业丰富的基础设施的可用性预计将推动单株抗体市场的成长。由于对更先进、更复杂的製造系统的需求不断增长以及政府对医疗基础设施现代化的大量投资，医疗保健产业正在新兴国家迅速扩张。

研究机构领域预计在预测期内复合年增长率最高

预计研究机构部门在预测期内的复合年增长率最高。由于癌症和其他慢性疾病的发生率在预期时间内增加，一些组织正在加强其研究方案并利用收到的资金来开发新技术。研究机构利用公共或商业性资金对目前或未来的产品进行研究，这些产品可用于诊断、治疗或监测任何人类疾病。

占比最大的地区：

由于存在标准的国家医疗保健系统和重要公司的存在，预计北美在预测期内将占据最大的市场占有率。在製造业中采用尖端基因工程技术、先进的医疗保健系统、政府对感染控制和管理的支持以及与久坐生活方式相关的疾病盛行率的上升，正在推动市场的成长。

复合年增长率最高的地区：

预计亚太地区在预测期内将维持最高的复合年增长率。促进市场扩张的因素包括对功能改进的遗传平台的技术需求不断增加、基因组学领域研发活动的扩大以及患者对单株抗体（mAb）疗法潜在益处的认识的提高。研究和开发行业的扩张以及单株抗体生产的技术进步也支持了市场的成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球中和抗体市场：按抗体类型

  • 单株抗体
  • 多克隆抗体
  • 广泛中和抗体
  • 交叉中和抗体
  • 其他类型的抗体

第六章全球中和抗体市场：依目标病毒分类

  • SARS-CoV-2
  • 流感
  • HIV
  • 伊波拉
  • C型肝炎
  • 兹卡热
  • 其他目标病毒

第七章全球中和抗体市场：依配销通路

  • 代理销售
  • 网路零售

第八章全球中和抗体市场：依应用分类

  • 诊断
  • 治疗
  • 研究与开发
  • 其他用途

第九章全球中和抗体市场：依最终用户分类

  • 医院
  • 製药公司
  • 实验室
  • 其他最终用户

第十章全球中和抗体市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • GlaxoSmithKline plc
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • Sanofi SA
  • AstraZeneca PLC
  • Merck & Co.Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Moderna, Inc.
  • Johnson & Johnson
  • BioNTech SE
  • CSL Limite
  • Sinovac Biotech Ltd
  • HaemaLogiX Ltd
Product Code: SMRC24617

According to Stratistics MRC, the Global Neutralizing Antibody Market is accounted for $190.4 billion in 2023 and is expected to reach $385.4 billion by 2030 growing at a CAGR of 10.6% during the forecast period. The immune system produces a kind of antibody known as neutralizing antibodies, which are designed to selectively target and inhibit the action of pathogens like bacteria or viruses. These antibodies stop pathogens from infecting or harming host cells by binding to particular areas, frequently on their surface. These antibodies aid the immune system in managing and curing the infection by blocking the pathogen's capacity to enter cells or multiply.

According to the report of GLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market.

Market Dynamics:

Driver:

Rising numbers of infectious diseases

Infectious disorders including hepatitis, HIV/AIDS, and respiratory infections are still quite common around the world. A promising therapeutic strategy for the management of these illnesses is the use of neutralizing antibodies. Neutralizing antibodies should become more and more in demand as the incidence of these infectious illnesses rises. Furthermore, it is anticipated that the market would rise in response to the rising prevalence of autoimmune illnesses.

Restraint:

Regulatory challenges

Securing regulatory clearance for novel antibody treatments necessitates thorough assessments of their safety and effectiveness. Comprehensive clinical data is frequently required by regulatory bodies, which might result in lengthier development times and higher costs. Companies may find it difficult to navigate the regulatory environment, particularly when it comes to unique or complicated neutralizing antibodies. The market may be severely constrained by regulatory issues.

Opportunity:

Improvements in antibody engineering and design

Neutralizing antibodies that are optimized can be produced thanks to the ongoing advancements in antibody engineering and design approaches. Affinity maturation and antibody humanization are two techniques used to improve the safety, half-life, and effectiveness of antibodies. Adding new platforms to the mix, including antibody fragments and antibody-drug conjugates, increases the potential for developing therapeutics. This is the main factor driving the market's expansion.

Threat:

Expensive development and treatment costs

The process of creating and producing neutralizing antibodies is expensive and time-consuming. High development costs can be attributed to the considerable research and development activities, clinical trials, and manufacturing expenses. Furthermore, neutralizing antibody therapies might be prohibitively expensive, which may restrict accessibility, especially in healthcare systems with tight budgets and resources.

COVID-19 Impact:

The neutralizing antibody market has been significantly influenced by the COVID-19 pandemic. In order to treat and prevent COVID-19, neutralizing antibodies have been essential. Several monoclonal antibody treatments have been approved or authorized for usage in emergency situations. The market has grown significantly as a result of the spike in demand for neutralizing antibodies against SARS-CoV-2.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to be the largest during the forecast period. The need for goods containing monoclonal antibodies, the expansion of the pharmaceutical and biotechnology sectors, and the availability of enhanced infrastructure for the healthcare industry are all anticipated to fuel the growth of the monoclonal antibody market. The healthcare industry is expanding quickly in emerging countries as a result of the rising need for more advanced sophisticated manufacturing systems and large government investments to modernize healthcare infrastructure.

The research institutes segment is expected to have the highest CAGR during the forecast period

The research institutes segment is expected to have the highest CAGR during the forecast period, owing to the increased incidence of cancer and other chronic illnesses within the anticipated time frame, several organizations have enhanced their research protocols and utilized the funds received to create novel technologies. Funded by public or commercial sources, research institutes conduct investigations on current or forthcoming products that have the potential to be utilized for the diagnosis, treatment, or surveillance of any human ailment.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the presence of a standard nationwide healthcare system and the existence of significant critical companies. The employment of cutting-edge genetic engineering technology in manufacturing, a sophisticated healthcare system, government support for infection control and management, and a rise in the prevalence of diseases associated with sedentary lifestyles are some of the factors driving the market's growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Factors driving the market expansion include the rise in technical demand for genetic platforms with improved capabilities, the expansion of research and development activities in the field of genomics, and the growing awareness among patients about the potential benefits of monoclonal antibodies (mAb) therapy. The market's growth is also fueled by the expansion of the R&D industry and technical advancements in the manufacturing of monoclonal antibodies.

Key players in the market:

Some of the key players in Neutralizing Antibody market include GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Merck & Co.Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Moderna, Inc., Johnson & Johnson, BioNTech SE, CSL Limite, Sinovac Biotech Ltd and HaemaLogiX Ltd.

Key Developments:

In February 2022, Eli Lilly and Company announced that United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.

In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.

Antibody Types Covered:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Broadly Neutralizing Antibody
  • Cross Neutralizing Antibody
  • Other Antibody Types

Target Viruses Covered:

  • SARS-CoV-2
  • Influenza
  • HIV
  • Ebola
  • Hepatitis C
  • Zika
  • Other Target Viruses

Distribution Channels Covered:

  • Distributors
  • Online Retail

Applications Covered:

  • Diagnostics
  • Therapeutics
  • Research & Development
  • Other Applications

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neutralizing Antibody Market, By Antibody Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Polyclonal Antibodies
  • 5.4 Broadly Neutralizing Antibody
  • 5.5 Cross Neutralizing Antibody
  • 5.6 Other Antibody Types

6 Global Neutralizing Antibody Market, By Target Virus

  • 6.1 Introduction
  • 6.2 SARS-CoV-2
  • 6.3 Influenza
  • 6.4 HIV
  • 6.5 Ebola
  • 6.6 Hepatitis C
  • 6.7 Zika
  • 6.8 Other Target Viruses

7 Global Neutralizing Antibody Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Distributors
  • 7.3 Online Retail

8 Global Neutralizing Antibody Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostics
  • 8.3 Therapeutics
  • 8.4 Research & Development
  • 8.5 Other Applications

9 Global Neutralizing Antibody Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Laboratories
  • 9.5 Other End Users

10 Global Neutralizing Antibody Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GlaxoSmithKline plc
  • 12.2 Novartis AG
  • 12.3 Regeneron Pharmaceuticals, Inc.
  • 12.4 Roche Holding AG
  • 12.5 Eli Lilly and Company
  • 12.6 Sanofi SA
  • 12.7 AstraZeneca PLC
  • 12.8 Merck & Co.Inc.
  • 12.9 Pfizer Inc.
  • 12.10 Takeda Pharmaceutical Company Limited
  • 12.11 Moderna, Inc.
  • 12.12 Johnson & Johnson
  • 12.13 BioNTech SE
  • 12.14 CSL Limite
  • 12.15 Sinovac Biotech Ltd
  • 12.16 HaemaLogiX Ltd

List of Tables

  • Table 1 Global Neutralizing Antibody Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neutralizing Antibody Market Outlook, By Antibody Type (2021-2030) ($MN)
  • Table 3 Global Neutralizing Antibody Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Neutralizing Antibody Market Outlook, By Polyclonal Antibodies (2021-2030) ($MN)
  • Table 5 Global Neutralizing Antibody Market Outlook, By Broadly Neutralizing Antibody (2021-2030) ($MN)
  • Table 6 Global Neutralizing Antibody Market Outlook, By Cross Neutralizing Antibody (2021-2030) ($MN)
  • Table 7 Global Neutralizing Antibody Market Outlook, By Other Antibody Types (2021-2030) ($MN)
  • Table 8 Global Neutralizing Antibody Market Outlook, By Target Virus (2021-2030) ($MN)
  • Table 9 Global Neutralizing Antibody Market Outlook, By SARS-CoV-2 (2021-2030) ($MN)
  • Table 10 Global Neutralizing Antibody Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 11 Global Neutralizing Antibody Market Outlook, By HIV (2021-2030) ($MN)
  • Table 12 Global Neutralizing Antibody Market Outlook, By Ebola (2021-2030) ($MN)
  • Table 13 Global Neutralizing Antibody Market Outlook, By Hepatitis C (2021-2030) ($MN)
  • Table 14 Global Neutralizing Antibody Market Outlook, By Zika (2021-2030) ($MN)
  • Table 15 Global Neutralizing Antibody Market Outlook, By Other Target Viruses (2021-2030) ($MN)
  • Table 16 Global Neutralizing Antibody Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Neutralizing Antibody Market Outlook, By Distributors (2021-2030) ($MN)
  • Table 18 Global Neutralizing Antibody Market Outlook, By Online Retail (2021-2030) ($MN)
  • Table 19 Global Neutralizing Antibody Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Neutralizing Antibody Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 21 Global Neutralizing Antibody Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 22 Global Neutralizing Antibody Market Outlook, By Research & Development (2021-2030) ($MN)
  • Table 23 Global Neutralizing Antibody Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Neutralizing Antibody Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Neutralizing Antibody Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 26 Global Neutralizing Antibody Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 27 Global Neutralizing Antibody Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 28 Global Neutralizing Antibody Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.